Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Escalation Study to Assess the Safety, Pharmacokinetics and Efficacy of SL-1002 in Patients With Limb Spasticity

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 31 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SIL-1002 (Primary)
Indications Muscle spasticity
Focus Adverse reactions
Acronyms RAISE
Sponsors Saol Therapeutics

Most Recent Events

30 Oct 2024 According to a Saol Therapeutics media release, data from this study were presented at the Spasticity X Symposium in Houston, Texas.
30 Oct 2024 Results presented in a Saol Therapeutics Media Release.
19 Sep 2023 According to a Saol Therapeutics media release, topline data from the RAISE Limb Spasticity Trial expected in the second quarter of 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com